Metronidazol Polpharma (Metronidazole)

Metronidazole is taken up by susceptible anaerobic organisms and reduced by intracellular electron‑transport proteins. The reduction creates reactive nitro radicals that damage DNA and inhibit nucleic acid synthesis, leading to microbial cell death. A similar mechanism disrupts essential proteins in protozoa, giving the drug its broad antimicrobial activity.

The exact dose of Metronidazol Polpharma is set by the prescribing clinician. Dosage depends on the type and severity of the infection, the patient’s weight, renal and hepatic function, and any relevant clinical guidelines. Healthcare professionals tailor the regimen to achieve optimal therapeutic effect while minimising risk.

Metronidazol Polpharma is classified as Pregnancy Category B, indicating that animal studies have not shown risk and there are no well‑controlled human studies. It may be used when the potential benefit outweighs any potential risk. Limited data are available for breastfeeding, so clinicians should evaluate the risk‑benefit ratio for each mother‑infant pair.

To request Metronidazol Polpharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing a formal quote that includes pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Metronidazol Polpharma contains the same active ingredient, metronidazole, as other nitroimidazole products. Differences lie mainly in formulation, manufacturing standards, and regulatory approvals. As an intravenous solution, it offers rapid systemic exposure suitable for severe infections, whereas oral tablets are used for milder cases. Clinical efficacy and safety are comparable when used according to guidelines.

Metronidazol Polpharma should be stored at controlled room temperature, typically below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct light, and avoid freezing. Follow any additional instructions on the label to maintain product stability and potency.

Metronidazol Polpharma is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, who dilutes the product in an appropriate compatible fluid and infuses it over the prescribed period. The exact infusion rate and duration are determined by the prescriber based on the infection being treated.

Serious adverse reactions, although uncommon, include seizures, peripheral neuropathy (often presenting as numbness or tingling in the limbs), and severe allergic responses such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for neurological symptoms or signs of hypersensitivity, and treatment should be discontinued immediately if these events occur.

Metronidazol Polpharma is contraindicated in individuals with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is advised for patients with severe hepatic impairment, and it should be avoided in those with a history of seizures unless the benefits clearly outweigh the risks. Pregnant women in the first trimester should discuss alternatives with their clinician.